Tuesday 24 June 2014
Dabrafenib (trade name Tafinlar) is a drug for the treatment of cancers associated with a mutated version of the gene BRAF .
Dabrafenib acts as an inhibitor of the associated enzyme B-Raf (BRAF ), which plays a role in the regulation of cell growth.
Dabrafenib has clinical activity with a manageable safety profile in clinical trials of phase 1 and 2 in patients with BRAF(V600)-mutated metastatic melanoma.
72% ORR to dabrafenib in paediatric patients with BRAF V600E-mutated low-grade glioma in BRAF V600-mutated population., setting the scene for BRAFi / MEKi combinations